BTG acquires novel opioid agonist for post-operative pain control from CLL Pharma

22-Feb-2007

BTG plc announced that it has acquired an opioid agonist for the control of post-operative pain from CLL Pharma, a drug development company based in Nice, France, in return for undisclosed milestone and royalty payments.

The compound, to be called BTG6001, is an orally active opioid agonist with a long duration of action, potentially reducing the amount of analgesic required for effective pain control. Owing to its unique receptor profile, BTG6001 is also expected to show a superior side effect profile compared with current opiate analgesics. BTG plans to complete preclinical development and initiate Phase I clinical studies during 2008.

Other news from the department business & finance

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance